Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by bilosellhion Apr 24, 2005 6:27pm
271 Views
Post# 8949840

RE: Amarath & Mellon

RE: Amarath & Melloncarmyk The first thing pointed out in my initial post that you responded to was the March 9, 2005 SEC filing showing that Newton bought more oncy in 2005 and later, I asked if there could be any doubt whether oncy would again be among their top negative contributors for 1st quarter ending mar 31, 2005, especially since oncy’s weighting likely increased with the addition of shares. so your spin that I was suggesting the “loser” should have been dumped in early 2005 has no basis. The main point was and remains, adding more of a “loser” stock that continues to make your top negative contributors list quarter after quarter when you are already under-performing vs the standard indices for the last 5 years isn’t exactly conservative investing or going to endear you to your shareholders (unless perhaps they are oncy shareholders) if things don’t turn around “soon”. How long does this under-performing fund manager have to give onc to start performing (or at least matching the nasdaq biotech index)? Perhaps more importantly, how long does the fund manager think s/he has? At what point do they decide they have no choice but to sell this “loser” if it keeps losing like it has the last 2+ quarters (and being flat for the quarter before that)? I suggest the more 5 year under-performing stock they add to a 5 year under-performing fund, the greater the pressure to produce results, especially on that 5 year under-performing stock. How has onc management performed so far under “pressure”? Dean curtis, Ontario teacher’s pension fund, Pfizer, anyone??? Apparently onc management has been too busy feeding the likes of BIOEYE/confucus/qzr4 & others with “information” to share on message boards to notice any “pressure” to perform.
Bullboard Posts